Recent studies have provided strong evidence for the emergence of substantial numbers of constitutively active ESR1 mutations in estrogen-receptor positive metastatic breast cancer that are undetected in primary disease. Some of these mutants remain partially sensitive to current anti-estrogen therapies but effective therapeutics targeted at them may require new approaches.